StreetInsider.com News Articles

Form 8-K Edesa Biotech, Inc. For: Oct 23

Fri, 23 Oct 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20261023/27228681.html

FDA clears Edesa Biotech IND for Phase 2 vitiligo drug study

Thu, 15 Oct 2026 09:15:30 -0400

Edesa Biotech, Inc. (Nasdaq: EDSA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 2 clinical study of EB06, a monoclonal antibody candidate, in patients with vitiligo. The clearance allows the Toronto-based company to expand recruitment to the United States, where the first investigational sites are expected to begin enrolling subjects next quarter.

Patient recruitment is already underway in Canada. The company anticipates topline data will be available in the fourth quarter of 2027, according to a press release.

The double-blind, placebo-controlled study will evaluate EB06 in up to 80 adults with moderate-to-severe

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

Thu, 15 Oct 2026 09:15:00 -0400

Enables expansion of ongoing vitiligo clinical study to U.S. investigational sites
Topline data anticipated Q4 2027

TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment to the United States. Patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter.

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

Thu, 15 Oct 2026 09:15:00 -0400

Enables expansion of ongoing vitiligo clinical study to U.S. investigational sites
Topline data anticipated Q4 2027

Form 8-K Edesa Biotech, Inc. For: Oct 15

Thu, 15 Oct 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20261015/27190973.html

Form 4 Edesa Biotech, Inc. For: Oct 05 Filed by: Nijhawan Pardeep

Tue, 06 Oct 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20261006/27156291.html

Form SCHEDULE 13G Edesa Biotech, Inc. Filed by: Stonepine Capital Management, LLC

Wed, 26 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260826/26982384.html

Form SCHEDULE 13G Edesa Biotech, Inc. Filed by: Stonepine Capital Management, LLC

Wed, 26 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260826/26982384.html

Form SCHEDULE 13D/A Edesa Biotech, Inc. Filed by: Nijhawan Pardeep

Tue, 25 Aug 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260825/26975899.html

Form SCHEDULE 13D/A Edesa Biotech, Inc. Filed by: Nijhawan Pardeep

Tue, 25 Aug 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260825/26975899.html

Form SCHEDULE 13D/A Edesa Biotech, Inc. Filed by: Velan Capital Investment Management LP

Tue, 25 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260825/26975270.html

Form SCHEDULE 13D/A Edesa Biotech, Inc. Filed by: Velan Capital Investment Management LP

Tue, 25 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260825/26975270.html

Form 8-K Edesa Biotech, Inc. For: Aug 19

Thu, 20 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260820/26956384.html

Form 8-K Edesa Biotech, Inc. For: Aug 19

Thu, 20 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260820/26956384.html

Form 424B5 Edesa Biotech, Inc.

Thu, 20 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26956270.html

Form 424B5 Edesa Biotech, Inc.

Thu, 20 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26956270.html

Edesa Biotech prices $25M public offering on Nasdaq

Wed, 19 Aug 2026 22:20:15 -0400

Edesa Biotech, Inc. (Nasdaq: EDSA) announced the pricing of an underwritten public offering expected to generate approximately $25.0 million in gross proceeds, before underwriting discounts, commissions, and other estimated expenses.

The Toronto-based clinical-stage biopharmaceutical company said the offering consists of 3,870,500 common shares with accompanying warrants to purchase an equal number of common shares, along with pre-funded warrants to purchase up to 675,000 common shares with accompanying warrants. The combined public offering price per common share and accompanying warrant is $5.50. The accompanying common share warrants carry an exercise price of $7.50 per share.

The warrants are immediately exercisable upon issuance and

Edesa Biotech prices $25M public offering on Nasdaq

Wed, 19 Aug 2026 22:20:15 -0400

The warrants are immediately exercisable upon issuance and

Edesa Biotech prices $25M public offering on Nasdaq

Wed, 19 Aug 2026 22:20:15 -0400

The warrants are immediately exercisable upon issuance and

Edesa Biotech prices $25M public offering on Nasdaq

Wed, 19 Aug 2026 22:20:15 -0400

The warrants are immediately exercisable upon issuance and

Edesa Biotech Announces Pricing of $25.0 Million Public Offering